ATC Abstracts

American Transplant Congress abstracts

Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience

Liver Institute, Methodist Dallas Medical Center, Dallas, TX.

Meeting: 2015 American Transplant Congress

Abstract number: A195

Keywords: , , ,

Session Information

Date: Saturday, May 2, 2015

Session Name: Poster Session A: Liver Transplantation: Viral Hepatitis

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is lacking. Methods: In a 10-year period, we compared: 19 OLT Rx, for 12 weeks, with TVR + Pegylated interferons (P-IFN) + Ribavirin (RBV) followed with conventional Rx (C-Rx, P-IFN+RBV) for 12-36 weeks. Controls (n=19) received C-Rx for 48 weeks. Matching done for age, gender, genotype (all 1), race, OLT date, non-responders (NR), SVR, immunosuppression (tacrolimus + Mycophenolic acid) and survival. Rx criteria HCVR histology (bx, stages 0-3, Batts&Ludwig classification). Pre and post Rx bx + annual bx and 3-year minimum follow up. Laboratory tests, graft and OLT survivals analyzed. Statitistics: t-, Chi2-tests. Results: No demographic , survival (matched controls) or laboratory differences found. Of note, 13/19 (68%) in TVR group were OLT NR to previous C-Rx. At 3+ years of follow up, there was significantly more HCVR progression in OLT TVR NR than TVR SVR (p < 0.05). Controls also showed differences in HCVR progression, although NS.

Liver Allograft Stage Changes with HCV Therapy
  Telaprevir + PegIFN +Ribavirin Rx PegIFN + Ribavirin
  Non Responders SVR Non Responders SVR
  (n = 6) (n = 13) (n = 6) (n = 13)
PreRx Stage 1.5±0.6* 1.7±1.3 2.0±0.9 1.9±0.9
EndRx Stage 2.2±0.8 2.6±1.3 2.8±1.2 2.0±
Last Follow up Stage 2.7±0.8* 2.1±1.4 2.8±1.2 2.0±
PreRx to Last Bx Difference 1.2±0.8** 0.4±0.7** 0.8±1.0 0.2±1.1
t-test: No differences, except * and **.Conclusions: With at least 3 years of follow up, HCV OLT SVR who received TVR triple Rx showed less HCVR progression. This benefit is in addition to the fact that 2/3 of OLT on TVR Rx had previously failed C-Rx. Newer antiviral agents, currently on trial, could show even superior results.

To cite this abstract in AMA style:

Fasola C, Mantry P, Weinstein J, Nazario H, Mubarak A, Barnes M, Habib A, Mejia A, Dickerman R, Cheng S. Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcome-of-liver-transplant-recipients-olt-with-hepatitis-c-recurrence-hcvr-who-achieved-postoperative-sustained-virologic-response-svr-after-combination-antiviral-therapy-rx-with-an/. Accessed January 28, 2021.

« Back to 2015 American Transplant Congress